Back to News
Market Impact: 0.36

Prediction: The Best Artificial Intelligence (AI) Growth Stocks on the Nasdaq Haven't Peaked Yet. Here's What I'm Buying.

AMZNMSFTMETANVDATELPATHNFLX
Artificial IntelligenceTechnology & InnovationCorporate EarningsCorporate Guidance & OutlookCompany FundamentalsAnalyst InsightsLegal & LitigationPatents & Intellectual Property

Credo Technology reported Q3 fiscal 2026 revenue of $407 million, up 202% year over year and 52% sequentially, with Q4 revenue guidance of $425 million to $435 million; UiPath posted fiscal 2026 revenue of $1.611 billion, up 13%, and achieved $57 million in GAAP operating income for the first time. The article is broadly bullish on both companies as AI infrastructure and enterprise orchestration beneficiaries, but highlights key risks including hyperscaler customer concentration for Credo and competitive pressure from Microsoft and other platform vendors for UiPath. Credo also resolved patent disputes with TE Connectivity and Molex, removing a legal overhang.

Analysis

The better read-through is that AI capex is bifurcating into a few economically powerful picks-and-shovels layers, not just the compute vendors. That tends to extend the cycle because interconnect and orchestration are not easily swapped out once designed into a deployment, which means the spending pool becomes stickier and more diversified across the stack. The second-order implication is margin pressure for the largest platform vendors if they have to keep financing more of the enablement layer internally while still paying external suppliers for critical performance bottlenecks. Credo is the purer leverage play, but its setup is more fragile than the headline growth suggests: when a customer buys infrastructure at this stage, it is often a multi-quarter design win inflection rather than a linear demand curve. That creates a near-term upside path if hyperscaler spend remains elevated, but also a sharp air-pocket risk if any one buyer pauses orders for even one quarter. The most important variable is not revenue growth itself; it is whether the company can convert current adoption into second-source resistance before competitors close the efficiency gap. UiPath is a different kind of opportunity: the market is still pricing it like a mature automation vendor while the product is moving up the stack into workflow control for agentic AI. The key second-order effect is budget reallocation inside enterprises — if orchestration becomes a governance necessity, it can become harder for Microsoft-style bundled alternatives to fully absorb the spend. But that thesis needs proof over the next 2-4 quarters in net retention and large deal size; otherwise the stock remains vulnerable to compression because execution risk is now about ecosystem relevance, not product fit. The contrarian point is that the current enthusiasm may still underappreciate how much of the AI winner list is now “enablers of enablers.” That is bullish for specialized names until hyperscaler capex slows, but it also means these stocks can de-rate faster than the mega-caps if the market shifts from growth scarcity to margin scrutiny. In other words: the upside is real, but the multiple is hostage to one variable — persistence of spending intensity through the next budget cycle.